What happens when the insurance company's first line of response is to deny, deny, deny? How does this increase in oversight from third-party payors impact the process of rare pituitary disease medicine authorizations indicated for treatment? Why do insurance companies use these delay tactics? What role do treatment guidelines play? What can we do? In this podcast, PWN cofounder Dr. Lewis Blevins shares his experiences and frustration with these problematic issues.